Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Just saw Glenmark got FDA green light for their fluticasone propionate inhaler - basically a generic version of GSK's FloVent that's been dominating the asthma market. They're calling it bioequivalent and got 180 days of market exclusivity, which is pretty solid.
What caught my eye though - FloVent was pulling in like $520 million a year, so there's real money in respiratory generics. Glenmark started rolling it out in March and the stock's been bouncing around between 1,327 to 2,286 rupees over the past year. Hit 2,040 at one point.
Think they can actually take meaningful share from GSK? Generic inhalers usually see decent adoption since access and price matter for asthma patients. Curious if this moves their needle for Q2 earnings or if it's too early to tell.